Importance: Retinoblastoma survivors are at risk for adverse oculo-visual outcomes. Limited data are available regarding long-term vision-targeted health-related quality of life (HRQoL) of adult retinoblastoma survivors. Objective: To examine vision-targeted HRQoL as reported on the 25-item National Eye Institute Visual Field Questionnaire for overall and specific scale scores among adult survivors of retinoblastoma. Design, Setting, and Participants: The Retinoblastoma Survivor Study is a retrospective cohort of adult retinoblastoma survivors treated at 3 academic medical centers in New York between 1932 and 1994. Participants completed a comprehensive questionnaire between April 2008 and June 2010. Items were scored in January 2013 and preliminary analyses were performed in July 2015. Models were finalized in May 2017. Main Outcomes and Measures: Self-reported vision-targeted HRQoL as reported on the 25-item National Eye Institute Visual Field Questionnaire. Items are scored from 0 to 100, with 100 representing the highest quality of life. Results: Among 470 adult retinoblastoma survivors (53.6% with bilateral disease; 52.1% female; 86.4% white and non-Hispanic; mean age at study, 43.3 years; range, 18.0-77.0 years), 86% had at least 1 eye removed (1 eye, 74.5%; both eyes, 11.5%); 56.5% were previously treated with radiotherapy; and 61.3% rated their eyesight as excellent/good while 16.2% reported complete blindness. The overall mean (SD) VFQ composite score for all survivors was 81.1 (17.2) (mean [SD] score for unilateral retinoblastoma survivors, 91.4 [7.7]; bilateral retinoblastoma survivors, 72.3 [18.2]; difference between survivors with unilateral and bilateral disease, 19.1 [95% CI, 16.5-21.7; P < .001]). Prior exposure to radiotherapy was not associated with decreased overall VFQ (β = -0.08; 95% CI, -0.15 to 0.002; P = .06) but was related to a few specific subdomains of visual functioning. Conclusions and Relevance: These findings suggest retinoblastoma-related oculo-visual problems are associated with functional status and vision-targeted HRQoL of adult survivors, particularly among those with bilateral disease.
Importance: Retinoblastoma survivors are at risk for adverse oculo-visual outcomes. Limited data are available regarding long-term vision-targeted health-related quality of life (HRQoL) of adult retinoblastoma survivors. Objective: To examine vision-targeted HRQoL as reported on the 25-item National Eye Institute Visual Field Questionnaire for overall and specific scale scores among adult survivors of retinoblastoma. Design, Setting, and Participants: The Retinoblastoma Survivor Study is a retrospective cohort of adult retinoblastoma survivors treated at 3 academic medical centers in New York between 1932 and 1994. Participants completed a comprehensive questionnaire between April 2008 and June 2010. Items were scored in January 2013 and preliminary analyses were performed in July 2015. Models were finalized in May 2017. Main Outcomes and Measures: Self-reported vision-targeted HRQoL as reported on the 25-item National Eye Institute Visual Field Questionnaire. Items are scored from 0 to 100, with 100 representing the highest quality of life. Results: Among 470 adult retinoblastoma survivors (53.6% with bilateral disease; 52.1% female; 86.4% white and non-Hispanic; mean age at study, 43.3 years; range, 18.0-77.0 years), 86% had at least 1 eye removed (1 eye, 74.5%; both eyes, 11.5%); 56.5% were previously treated with radiotherapy; and 61.3% rated their eyesight as excellent/good while 16.2% reported complete blindness. The overall mean (SD) VFQ composite score for all survivors was 81.1 (17.2) (mean [SD] score for unilateral retinoblastoma survivors, 91.4 [7.7]; bilateral retinoblastoma survivors, 72.3 [18.2]; difference between survivors with unilateral and bilateral disease, 19.1 [95% CI, 16.5-21.7; P < .001]). Prior exposure to radiotherapy was not associated with decreased overall VFQ (β = -0.08; 95% CI, -0.15 to 0.002; P = .06) but was related to a few specific subdomains of visual functioning. Conclusions and Relevance: These findings suggest retinoblastoma-related oculo-visual problems are associated with functional status and vision-targeted HRQoL of adult survivors, particularly among those with bilateral disease.
Authors: Jennifer van Dijk; Kim J Oostrom; Jaap Huisman; Annette C Moll; Peggy T Cohen-Kettenis; Peter J Ringens; Saskia M Imhof Journal: Pediatr Blood Cancer Date: 2010-01 Impact factor: 3.167
Authors: Danielle Novetsky Friedman; Joanne F Chou; Kevin C Oeffinger; Ruth A Kleinerman; Jennifer S Ford; Charles A Sklar; Yuelin Li; Mary S McCabe; Leslie L Robison; Brian P Marr; David H Abramson; Ira J Dunkel Journal: Cancer Date: 2016-01-11 Impact factor: 6.860
Authors: Jennifer S Ford; Joanne F Chou; Charles A Sklar; Kevin C Oeffinger; Danielle Novetsky Friedman; Mary McCabe; Leslie L Robison; Ruth A Kleinerman; Yuelin Li; Brian P Marr; David H Abramson; Ira J Dunkel Journal: J Clin Oncol Date: 2015-09-28 Impact factor: 44.544
Authors: Jennifer van Dijk; Jaap Huisman; Annette C Moll; Antoinette Y N Schouten-van Meeteren; Pieter D Bezemer; Peter J Ringens; Peggy T Cohen-Kettenis; Saskia M Imhof Journal: Health Qual Life Outcomes Date: 2007-12-03 Impact factor: 3.186
Authors: Jennifer van Dijk; Saskia M Imhof; Annette C Moll; Peter J Ringens; Peggy T Cohen-Kettenis; Frank Rijmen; Jaap Huisman Journal: Health Qual Life Outcomes Date: 2007-06-04 Impact factor: 3.186
Authors: Joanne F Chou; Jennifer S Ford; Ruth A Kleinerman; David H Abramson; Jasmine H Francis; Charles A Sklar; Kevin C Oeffinger; Leslie L Robison; Ira J Dunkel; Danielle Novetsky Friedman Journal: Pediatr Blood Cancer Date: 2021-01-26 Impact factor: 3.167
Authors: Victoria W Willard; Ibrahim Qaddoumi; Haitao Pan; Chia-Wei Hsu; Rachel C Brennan; Matthew W Wilson; Carlos Rodriguez-Galindo; Kristin Goode; Kendra Parris; Sean Phipps Journal: J Clin Oncol Date: 2021-04-23 Impact factor: 50.717